Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.59 |
| ▸ | DHODH | Q02127 | 6/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607221 | 0.85 | CRHR1 (0.69) | CRHR1DHODHKDM4EALDH1A1MAPT | |
| SCHEMBL9750606 | 0.78 | P2RY1 (0.51) | DHODHP2RY1KDM4EALDH1A1MAPT | |
| SCHEMBL7229694 | 0.77 | ALDH1A1 (0.55) | DHODHP2RY1KDM4EALDH1A1MAPT | |
| SCHEMBL12158159 | 0.76 | DHODH (0.65) | DHODHP2RY1KDM4EALDH1A1MAPT | |
| SCHEMBL28342547 | 0.76 | ALDH1A1 (0.56) | DHODHP2RY1KDM4EALDH1A1MAPT | |
| SCHEMBL12158138 | 0.76 | DHODH (0.60) | DHODHP2RY1KDM4EALDH1A1MAPT | |
| SCHEMBL6928008 | 0.76 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL10480139 | 0.76 | P2RY1 (0.52) | DHODHP2RY1KDM4EALDH1A1MAPT | |
| SCHEMBL2309900 | 0.75 | ALDH1A1 (0.51) | DHODHP2RY1KDM4EALDH1A1MAPT | |
| SCHEMBL23742065 | 0.75 | HPGD (0.48) | DHODHP2RY1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320365-A4 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1320365-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | Bristol-Myers Squibb Company (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6515005-B2 | For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002024200-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | CRH, CRHR1, CRHR2 | CRHR1 2/4885DHODH 4430/4885P2RY1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.